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Background: Atrial fibrillation is the most common type of arrhythmia after cardiac surgery. An increasing body of
evidence demonstrates that oxidative stress plays a pivotal role in the pathophysiology of atrial fibrillation. N-
acetylcysteine (NAC) is a free radical scavenger, and may attenuate this pathophysiologic response and reduce the
incidence of postoperative AF (POAF). However, it is unclear whether NAC could effectively prevent POAF.
Therefore, this meta-analysis aims to assess the efficacy of NAC supplementation on the prevention of POAF.
Methods: Medline and Embase were systematically reviewed for studies published up to November 2011, in which
NAC was compared with controls for adult patients undergoing cardiac surgery. Outcome measures comprised the
incidence of POAF and hospital length of stay (LOS). The meta-analysis was performed with the fixed-effect model
or random-effect model according to the heterogeneity.
Results: Eight randomized trials incorporating 578 patients provided the best evidence and were included in this
meta-analysis. NAC supplementation significantly reduced the incidence of POAF (OR 0.62, 95% CI 0.41 to 0.93; P =
0.021) compared with controls, but had no effect on LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703).
Conclusions: The prophylactic NAC supplementation may effectively reduce the incidence of POAF. However, the
overall quality of current studies is poor and further research should focus on adequately powered randomized
controlled trials with POAF incidence as a primary outcome measure.
Background
Postoperative atrial fibrillation (POAF) is the most fre-
quent arrhythmia encountered following cardiac surgery,
affecting approximately 25-40% of patients [1-3].
Although the majority of POAF are benign and self-limit-
ing, it has been associated with an increase in both hospi-
tal length of stay (LOS) and total hospital costs [1,2,4,5].
The efficacy of pharmacologic interventions on
preventing POAF has been extensively researched [6,7].
Recent guidelines for the prevention and management of
POAF were published in 2011 jointly by the American
College of Cardiology, the AHA, and the European
Society of Cardiology [8]. Nevertheless, none of them are
effective for all patients and all of them have significant
limitations, the best prophylaxis to prevent POAF
remains to be established [9]. Despite the extensive stu-
dies, the pathphysiology of POAF are for the moment far
from being fully elucidated. In the past few years, a grow-
ing body of evidence suggests that oxidative stress has
been found to play a pivotal role in the pathophysiology
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pathogenesis of POAF [11].
Antioxidant N-acetylcysteine (NAC) seemed a promis-
ing and novel measure for the prevention of POAF. In a
prospective, randomized, placebo-controlled pilot study
in patients undergoing coronary artery bypass and/or
valve surgery, NAC significantly reduced the incidence
of POAF [12]. However, the results have contrasted in
seven other randomized controlled trials [13-19] in
which the effectiveness of NAC was assessed in patients
undergoing cardiac surgery. We therefore conducted a
meta-analysis based on relevant and available rando-
mized controlled trials to assess the efficacy of NAC
supplementation on the prevention of POAF for adult
patients undergoing cardiac surgery.
Methods
Literature search and selection criteria
A comprehensive search was undertaken to identify all
published randomized controlled trials of NAC versus
controls during cardiac surgery. Medline and Embase
were searched from the date of their inception to
November 1, 2011. Search terms included: “N-acetylcys-
teine”, “NAC”, “acetylcysteine”, “mucomyst” and “cardiac
surgery”, “cardiothoracic surgery”,"heart surgery”, “cardi-
opulmonary bypass”, “CPB”, “coronary artery bypass
graft”, “CABG”, “CAB”, “valve surgery”,a n d“valvular
surgery”. Results were limited to human subjects and
randomized controlled trials. We screened the reference
lists of included studies and related publications. The
results were then hand searched for eligible trials. We
did not include abstracts or meeting’s proceedings. This
search strategy was performed iteratively until no new
potential citations could be found on review of the
reference lists of retrieved articles.
We included studies in all languages irrespective of
blinding when the following inclusion criteria were met:
adult patients undergoing cardiac surgery; randomized
allocation to NAC group or control group (placebo or
routine treatment); and reporting data on the incidence
of POAF. Exclusion criteria included age < 18 years old,
and known allergy or hypersensitivity to NAC.
Data extraction and quality assessment
Two investigators (Wan-Jie Gu and Zhen-Jie Wu) inde-
pendently extracted the following information from each
study: first author’s name, surgery type (coronary artery
bypass graft [CABG], valve, or combination surgery),
study design (RCT, prospective or not), type of controls
(placebo or not), type of blinding (double-blinding or
not), NAC regimen, sample size, mean age, percentage
male, the incidence of POAF, and length of hospital stay
in each group. Disagreements were resolved through
discussion and consensus.
The methodological quality of the studies included in
the meta-analysis was independently scored by Wan-Jie
Gu and Zhen-Jie Wu using validated Jadad 5 point
scale. The scale consists of three items describing rando-
mization (0-2 points), masking (0-2 points), and drop-
outs and withdrawals (0-1 points) in the report of a
randomized controlled trial [20]. A score of 1 is given
for each of the points described. A further point is
obtained where the method of randomization and/or
blinding is given and is appropriate; whereas it is inap-
propriate a point is deducted. Higher scores indicate
better reporting.
Statistical analysis
We assessed the overall efficacy of NAC supplementa-
tion on the prevention of POAF based on the data from
the eight randomized trials. The incidences of POAF
were treated as dichotomous variables and were
expressed as odds ratio (OR) with 95% CI for each
study. LOS was treated as a continuous variable. For
comparison of LOS, the weighted mean difference
(WMD) with 95% CI was calculated as the difference
between the mean values of LOS in treatment and con-
trol groups. Pooled estimates of efficacy were calculated
using the Man-tel-Haenszel fixed-effects model [21]. If
there was heterogeneity, the following methods were
used to deal with it: (a) subgroup analysis; (b) sensitivity
analysis performed by excluding the trials which poten-
tially biased the results. If the heterogeneity still poten-
tially existed, the DerSimonian and Lair random-effects
model was used. A test for heterogeneity, defined as var-
iation among the results of individual trials for a given
treatment beyond that expected from chance, was used
to assess whether the magnitude of a given treatment
effect varied between the trials. We assessed heterogene-
ity with I
2, which describes the percentage of total varia-
tion across studies due to heterogeneity rather than
chance. I
2 can be calculated as: I
2 = 100% × (Q-df)/Q(Q
=C o c h r a n e ’s heterogeneity statistics, df = degrees of
freedom). Negative values of I
2 equaled zero, so that I
2
ranged between 0% (ie, no observed heterogeneity) and
100%. High values would show increasing heterogeneity
[22]. The presence of publication bias was evaluated by
using the Begg and Egger tests [23,24]. A two-tailed P-
value of less than 0.05 was judged as statistically signifi-
cant. All statistical analyses were performed using Stata
version 11 (Stata Corporation, College Station, TX,
USA).
Results
Identification of eligible studies
Eighty-three reports were identified by the initial litera-
ture retrieval, with limiting to human subjects and ran-
domized controlled trials. Through various means, we
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Page 2 of 8accessed all the full texts. After screening the title,
abstract and full texts, however, 75 studies were
excluded because they did not provide available data.
Consequently, the remaining 8 trials (n = 578 patients)
provided best evidence and were included in the current
meta-analysis [12-19]. The flow chart of search strategy
is shown in Figure 1.
Characteristics of eligible studies
The baseline characteristics of the included studies are
shown in Table 1 and design characteristics are presented
in Table 2. Of the 8 included trials, four were done in
Turkey [12-14,18], two in Canada [15,17], one in Ger-
many [16], and one in Korea [19]. The number of partici-
pants ranged from 20 [13,14] to 175 [17]. All trials
included both men and women. Five studies
[13-15,18,19] in this meta-analysis enrolled patients
undergoing CABG only. The remaining three studies
[12,16,17] included patients undergoing valvular or com-
bination CABG with valvular surgery, or both. NAC was
administered orally and/or intravenously by different
regimens and formulations. Seven studies [12-14,16-19]
used an intravenous route to administer NAC during the
perioperative period, and one study [15] used an oral
Figure 1 Search strategy.
Table 1 Baseline characteristics of the included studies
Reference NAC regimen N n Age (years) Male (%)
NAC Control NAC Control NAC Control
Ozaydin et al. [12] 50 mg/kg IV 1 h before surgery and 50
mg/kg/day for 48 h post-CTS
115 58 57 57 ± 11 59 ± 9 81 77.2
Eren et al. [13] 100 mg/kg IV for 1 h before CPB and
40 mg/kg/day at 24 h after CPB
20 10 10 61.1 ± 4.8 60.5 ± 5.7 80 70
Orhan et al. [14] 50 mg/kg IV at start of anesthesia induction for 30 min 20 10 10 59.6 ± 5.48 61.8 ± 4.32 70 60
El-Hamamsy et al.
[15]
600 mg orally the day before and the morning of the
operation,150 mg/kg IV before skin incision, then 12.5 mg/
kg/h IV for 24 h
100 50 50 59.8 ± 7.8 61.3 ± 7.4 86 92
Haase et al. [16]# 150 mg/kg IV bolus after anesthesia induction, then 50
mg/kg IV over 4 h, then 100 mg/kg IV over 20 h
60 30 30 68.9 ± 9.7 68.3 ± 9.3 77 70
Wijeysundera et
al. [17]
100 mg/kg IV after induction of anesthesia over
30 min, 20 mg/kg/h IV after CPB for 4 h
175 88 87 74 ± 8 73 ± 9 60 59
Peker et al. [18] 50 mg/kg IV for 1 h before surgery, 50
mg/kg/day IV for 48 h after the operation
40 19 21 60.00 ± 11.36 57.67 ± 8.57 89.5 85.7
Kim et al. [19] 100 mg/kg IV bolus over 15 min after anesthetic induction,
then IV infusion at 40 mg/kg/day for
24 h
48 24 24 60.8 ± 8.4 65.3 ± 7.6 87.5 91.7
Abbreviations: NAC, N-acetylcysteine; CPB, cardiopulmonary bypass; IV, intravenous; CTS, cardiothoracic surgery; #, history of AF; N, Number of participants
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tion postoperatively. The overwhelming majority of stu-
dies used weight-based dosing and started NAC just a
few hours prior to surgery. The overall incidence of
POAF varied between 5% [14] and 61.7% [17]. A total of
289 patients were allocated randomly to NAC group and
289 to control group. The quality of the included studies
was assessed by the Jadad score. The median Jadad score
of the studies included was 4 (range from 3 to 5).
POAF
POAF data were reported in all eight studies [12-19]
(578 patients; Table 2), and POAF was the primary end
point in one study [12]. Details of POAF outcome defi-
nition and assessment are presented in Table 3.
Analysis of pooled prevalence of preoperative patient
group characteristics revealed that no difference was
observed for history of coexistence of basic diseases (e.g.
diabetes mellitus, hypertension, congestive heart failure),
routine prophylactic therapies (e.g. b-blocker, angioten-
sin-converting enzyme inhibitor or angiotensin receptor
blocker, and calcium channel blocker; Table 4).
Pooling all eight randomized trials, 28.4% (82 of 289)
of patients given NAC and 36.0% (104 of 289) of con-
trols developed POAF. Meta-analysis of eight trials
using a fixed-effects model showed that NAC supple-
mentation significantly reduced the incidence of POAF
(OR 0.62, 95% CI 0.41 to 0.93; P = 0.021; Figure 2) com-
pared with controls, with little statistical heterogeneity
between the trials (I
2 = 8.3%, heterogeneity P = 0.366).
A trial conducted by Haase et al. [16] reported some
patients with pre-existing atrial fibrillation. The pooled
results didn’t significantly change when this trial was
excluded (OR 0.52, 95% CI 0.33 to 0.82; P = 0.005), and no
evidence of heterogeneity was observed among the remain-
ing seven studies (I
2 =0 . 0 % ,h e t e r o g e n e i t yP =0 . 6 2 2 ) .
Table 2 Design characteristics
POAF LOS(days)








NAC Control NAC Control




Placebo Yes 4 3/58 12/57 7.7 ± 3 7.9 ± 4.2
Eren et al. [13] CABG RCT
(prospective)
Placebo Yes 3 2/10 1/10 NA NA
Orhan et al. [14] CABG RCT Routine
protocol
No 3 0/10 1/10 7.2 ± 0.42 7.3 ± 0.48
El-Hamamsy et al. [15] CABG RCT
(prospective)
Placebo Yes 3 4/50 6/50 5.4 ± 2.3 5.3 ± 2.5
Haase et al. [16]# CABG and/or
valve





RCT Placebo Yes 5 50/88 58/87 NA NA
Peker et al. [18] CABG RCT
(prospective)
Placebo Yes 4 0/19 2/21 NA NA
Kim et al. [19] CABG RCT Placebo Yes 4 4/24 8/24 11.3 ± 6.3 10.5 ± 4.5
Abbreviations: NAC, N-acetylcysteine; POAF, postoperative atrial fibrillation; LOS, length of hospital stay; CABG, coronary artery bypass grafting; #, history of AF;
RCT, randomized controlled trial; NA, data not available
Table 3 Monitoring and definition of postoperative atrial fibrillation
Reference Monitoring of postoperative atrial fibrillation Definition of postoperative atrial fibrillation
Ozaydin et al. [12] ECGs performed continuously during the first 2
postoperative days in the intensive care unit
An irregular narrow complex rhythm (in the absence of bundle
branch block) with absence of discrete P-waves
Eren et al. [13] ECGs performed on the first postoperative day Not reported
Orhan et al. [14] Not reported Not reported
El-Hamamsy et al. [15] Not reported Not reported
Haase et al. [16] Not reported Not reported
Wijeysundera et al. [17] Continuous telemetry or 12-lead ECGs Any new atrial fibrillation
Peker et al. [18] ECGs performed continuously during the first 2
postoperative days in the intensive care unit
Not reported
Kim et al. [19] Not reported Not reported
ECG, electrocardiogram
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Five trials [12,14-16,19] reported the effect of NAC on
LOS, but only 4 trials [12,14,15,19] provided available
data (expressed as mean ± standard deviation) with a
total of 283 patients. The pooled analysis using a fixed-
effects model showed that NAC supplementation did
not significantly reduce LOS (WMD -0.07, 95% CI -0.42
to 0.28; P = 0.703; Figure 3), with no statistical hetero-
geneity between the trials (I
2 =0 . 0 % ,h e t e r o g e n e i t yP =
0.922).
Publication bias
Assessment of publication bias using Egger’s and Begg’s
tests showed that there was no potential publication
bias among the included trials (Egger’st e s t ,P = 0.275;
Begg’s test, P = 0.536, Figure 4).
Discussion
To the best of our knowledge, this is the first meta-ana-
lysis to assess the efficacy of NAC supplementation on
the prevention of atrial fibrillation after cardiac surgery.
Meta-analysis of all eight included trials using a fixed-
effects model illustrates that NAC supplementation can
effectively reduce the incidence of POAF in adult
patients undergoing cardiac surgery. In a recent meta-
analysis, Harling et al. [5] evaluated antioxidant vitamins
as a prophylactic method against POAF. This interven-
tion reduced POAF significantly with OR of 0.43 (95%
CI 0.21 to 0.89). Our results suggest that antioxidant
NAC supplementation is as effective as antioxidant vita-
mins in reducing POAF, with OR in the similar range,
being vitamins slightly more effective achieving this pur-
pose than NAC. In addition, one problem with the use
of antioxidant NAC to prevent POAF is that the major-
ity of patients does not develop POAF after cardiac sur-
gery but would still be exposed to possible side effects.
In this meta-analysis, three trials [12,17,18] reported
NAC-related adverse effects and the incidence of post-
operative complications was similar in both NAC and
control groups.
The mechanisms that antioxidant NAC supplementa-
tion reduces the incidence of POAF are not entirely
known. However, there is now an increasing body of
evidences that oxidative stress [11], inflammation
[25,26], and rennin-angiotensin system [27,28] are
involved in the pathogenesis of POAF.
Table 4 Perioperative variables of the patients
Variable NAC [% (n)] Control [% (n)] X
2 value P value Total prevalence [% (n)]
Diabetes mellitus [12,14,16,17,19] 33.8 (71/210) 30.8 (64/208) 0.442 0.506 32.3 (135/418)
Hypertension [12,14,16,17,19] 70.5 (148/210) 69.7 (145/208) 0.029 0.864 70.1 (293/418)
Congestive heart failure [17] 19.3 (17/88) 18.4 (16/87) 0.025 0.875 18.9 (33/175)
b-blocker [12,15,17,19] 75.9 (167/220) 73.4 (160/218) 0.366 0.545 74.7 (327/438)
ACEI or ARB [12,15,17,19] 64.1 (141/220) 60.1 (131/218) 0.744 0.388 62.1 (272/438)
Calcium channel blockers [15,17,19] 40.1 (65/162) 34.8 (56/161) 0.983 0.321 37.5 (121/323)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker
Figure 2 Incidence of postoperative atrial fibrillation (fixed effect model). CI, confidence interval; OR, odds ratio.
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and perpetuation of POAF is an interesting subject.
NAC is a glutathione precursor; by entering cells and
being hydrolyzed to cysteine, it stimulates glutathione
synthesis, scavenges free radicals, and terminates the
propagation of free radical reactions [29]. In addition, it
also has potent anti-inflammatory effects by reducing
the production of pro-inflammatory cytokines [30,31]
and blocks rennin-angiotensin system and/or atrial
remodelling via its anti-inflammatory and antioxidant
actions [32].
Aranki et al. [33] demonstrated that atrial fibrillation
is a major predictor of longer hospitalization and found
that it was independently associated with LOS extended
by 4.9 days. NAC supplementation did not significantly
reduce the LOS in this meta-analysis. The total inci-
dence of POAF is 32.2% (156 of 578), fewer than half of
patients develop POAF and still fewer develop pro-
longed atrial fibrillation, so the effect of NAC on LOS
in patients prone to atrial fibrillation would have to be
v e r yl a r g et ob ea b l et od e t e c ta ne f f e c to fL O Si nt h e
total population. In addition,ar e l a t i v e l ys m a l ln u m b e r
of samples (only four studies) provided available data on
LOS, additional studies or data are warranted.
This meta-analysis has several potential limitations
that should be taken into account. First, we acknowl-
e d g e dt h a tt h em e t a - a n a l y s i si n c l u d e dt h er e l a t i v e l y
small number of patients in the individual studies (n <
Figure 3 Effects of N-acetylcysteine on hospital length of stay (days). WMD, weighted mean difference.
Figure 4 Tests for publication bias for OR of the incidence of POAF.
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lack of complete availability of relevant data, particularly
for LOS. Second, only one study [12] included in the
present meta-analysis has used POAF as a primary out-
come measure, but for the remaining seven studies
[13-19], POAF is only one of the clinically significant
end points consistently reported rather than a primary
outcome measure. Next, these studies lack homogeneity
in both the method of postoperative monitoring and in
their definition of POAF. This leads to potential under-
estimation and/or overestimation of the true incidence
of POAF. Finally, because of sparse and inconsistent
reporting across trials, we were unable to assess the
impact of variations in the use of routine prophylactic
therapies (e.g. statins, diuretics, NSAID or COX-2 inhi-
bitor, and aspirin etc.), coexistence of basic diseases (e.g.
myocardial infarction etc.), and other factors on our
meta-analytic conclusions.
Future research should therefore focus on an ade-
quately powered multicentre large-scale double-blind
placebo-controlled randomized trial. Furthermore, novel
studies should aim to treat the incidence of POAF as a
primary outcome measure, and standardize POAF
reporting criteria and antioxidant protocol. It is also
need to exclude the synergistic effects of other coexisted
drugs and antioxidant NAC on POAF.
Conclusion
This meta-analysis indicates that prophylactic NAC sup-
plementation effectively reduces the incidence of POAF
for adult patients undergoing cardiac surgery. Further
research should focus on adequately powered RCTs
with POAF incidence as a primary outcome measure.
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